Xiaorui Su
Overview
Explore the profile of Xiaorui Su including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
582
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao K, Deng Y, Su X, Hu W, Yin T, Yang X, et al.
World Neurosurg
. 2025 Feb;
196:123740.
PMID: 39929267
Background: Different from typical primary central nervous system lymphoma (PCNSL), early-stage atypical PCNSL usually presents as patchy signal abnormalities without evident mass effect or significant contrast enhancement and is prone...
2.
Su X, Hu P, Li D, Zhao B, Niu Z, Herget T, et al.
Nat Biomed Eng
. 2025 Jan;
PMID: 39789329
Graph representation learning has been leveraged to identify cancer genes from biological networks. However, its applicability is limited by insufficient interpretability and generalizability under integrative network analysis. Here we report...
3.
Li G, Zhao B, Su X, Yang Y, Zeng Z, Hu P, et al.
Comput Biol Med
. 2025 Jan;
186:109625.
PMID: 39756188
N-methyladenosine (mA) plays a crucial role in enriching RNA functional and genetic information, and the identification of mA modification sites is therefore an important task to promote the understanding of...
4.
Shen W, Cui C, Su X, Zhang Z, Velez-Arce A, Wang J, et al.
Res Sq
. 2024 Dec;
PMID: 39678335
Modeling molecular activity and quantitative structure-activity relationships of chemical compounds is critical in drug design. Graph neural networks, which utilize molecular structures as frames, have shown success in assessing the...
5.
Wang J, Zhang M, Sun Y, Su X, Hui R, Zhang L, et al.
Life Sci
. 2024 Dec;
361:123290.
PMID: 39638282
Background: Methamphetamine (METH) is a potent psychostimulant that interferes the functionality of various brain regions and nervous connections, leading to addiction. The nucleus accumbens core (NAcC), primarily composed of gamma-aminobutyric...
6.
Hu W, Shao H, Yang X, Zheng L, Li S, Tan Q, et al.
Quant Imaging Med Surg
. 2024 Oct;
14(10):7740-7748.
PMID: 39429581
No abstract available.
7.
Zhang R, Song Z, Su X, Li T, Xu J, He X, et al.
Med Mycol
. 2024 Aug;
62(9).
PMID: 39174486
This study analyzed the prevalence and antifungal susceptibility of superficial fungal infections in 295 cases from 2019 to 2020 at a dermatology clinic. Dermatophytes were the predominant pathogens (69.5%), including...
8.
Su X, Zhao B, Li G, Zhang J, Hu P, You Z, et al.
IEEE J Biomed Health Inform
. 2024 Jun;
29(3):1771-1781.
PMID: 38917286
Uncovering novel drug-drug interactions (DDIs) plays a pivotal role in advancing drug development and improving clinical treatment. The outstanding effectiveness of graph neural networks (GNNs) has garnered significant interest in...
9.
Su X, Li Y, Ren Y, Cao M, Yang G, Luo J, et al.
Biomed Pharmacother
. 2024 Jun;
176:116902.
PMID: 38870626
Drug resistance in hepatocellular carcinoma has posed significant obstacles to effective treatment. Recent evidence indicates that, in addition to traditional gene mutations, epigenetic recoding plays a crucial role in HCC...
10.
Ren Y, Li Y, Cao M, Tang Y, Yuan F, Yang G, et al.
Chin J Cancer Res
. 2024 May;
36(2):114-123.
PMID: 38751440
Objective: Unresectable hepatocellular carcinoma (uHCC) continues to pose effective treatment options. The objective of this study was to assess the efficacy and safety of combining low-dose cyclophosphamide with lenvatinib, pembrolizumab...